Tyra Biosciences price target raised to $25 from $23 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Tyra Biosciences to $25 from $23 and keeps a Buy rating on the shares. The firm says the Phase 1 urothelial carcinoma data in the second half of 2024 could risk-mitigate the thesis of selective FGFR inhibition versus pan-FGFR inhibition. Tyra remains on track to present initial SURF301 data in 2024, which, if positive, should provide validation for the SNAP platform and for the selective FGFR inhibition strategy, risk-mitigating the pipeline, the analyst tells investors in a research note.